Sign in
Taking people in United StatesEarly phase 1

Umbilical cord tissue injections for knee osteoarthritis, tested for safety

Tests different doses of Wharton's Jelly injections in knee osteoarthritis.

Key facts

Who runs it
R3 Medical Research
Where
Beverly Hills, Cleveland, Fresno, New York, and Scottsdale, United StatesSee the 5 sites
Trial code
Registry title
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis
Status
Recruiting
Phase
Early phase 1
People taking part
120 people, planned
Started
1 Oct 2024
Expected to end
1 Oct 2029
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection
Record updated
23 September 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults over age 30 with knee osteoarthritis (wear-and-tear arthritis) in one knee and knee pain. They get one knee injection of Wharton's Jelly allograft tissue from an umbilical cord at a low, medium or high dose.

Age
Over age 30
Sex
All sexes can join. Women must be abstinent, surgically sterilized or postmenopausal. Premenopausal women must have a negative pregnancy test, use birth control and not plan a pregnancy during the study.
Disease stage
Grade II or III osteoarthritis on the KL scale in one knee. Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS). Body Mass Index (BMI) <50Kg/m2.
Earlier treatment
No pain medicine, including NSAIDs, within 2 weeks before the injection. No joint injection in that knee, including viscosupplementation, in the past 6 months. No surgery on that knee in the past 6 months.

Main reasons for not taking part

  • Use of blood thinners (anticoagulants) or immune-suppressing medicines
  • Past organ or blood (hematologic) transplant, rheumatoid arthritis or other autoimmune disease
  • Cancer (carcinoma) diagnosed within the past 2 years
  • Knee infection, or antibiotics for a knee infection, in the past 3 months, or a knee injury in the past 3 months
  • Pregnant or breastfeeding women, or a known allergy to amphotericin-B, ciprofloxacin, gentamycin, penicillin or streptomycin

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Be over age 30
  • Diagnosed with Grade II or III OA on the KL scale (in one knee)
  • Body Mass Index (BMI) <50Kg/m2
  • Pain score of 4 or more on the Numeric Pain Rating Scale (NPRS)
  • Female patients must be abstinent, surgically sterilized or postmenopausal
  • Premenopausal females must have a negative pregnancy test, on contraceptive measures and do not anticipate pregnancy during the duration of the study
  • Be willing and capable of giving written informed consent to participate in English
  • Be willing and capable of complying with study-related requirements, procedures and visits in English

Who cannot take part

  • Have taken any pain medication including nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to study injection date
  • Use anticoagulants have a substance abuse history and fail to agree not to take any knee-symptom modifying drugs during the course of the study without discussing and reporting the use to the site principal investigator and study team
  • Have had an intra-articular injection of any drug including viscosupplementation in the index knee in the past 6 months
  • Have had surgery on the index knee with the past 6 months
  • Planned elective surgery during the course of the study
  • Be on immunosuppressive medications
  • Have participated in any other clinical trial or treatment (not just for the knee, but for any reason) with any investigational product within the past 30 days prior to inclusion of study
  • A history of organ or hematologic transplantation, rheumatoid arthritis, or other autoimmune disorders
  • Have a knee infection or have used antibiotics for knee infection within the past 3 months
  • Serious neurological, psychological or psychiatric disorders
  • Have a known drug allergy to amphotericin-B, ciprofloxacin, gentamycin, penicillin, or streptomycin
  • Had a traumatic injury to the index knee with the past 3 months
  • Have a diagnosis of carcinoma with the past 2 years
  • Female patients who are breast feeding or are pregnant or desire to become pregnant during the course of the study
  • Contraindications to radiographic or MRI imaging
  • Injury or disability claims under current litigation or pending or approved workers compensation claims

Where in United States

  • R3 Anti Aging Beverly HillsBeverly Hills, United StatesContact: Neville Campbell, MDTaking people
  • Dr. Duc (Steve) Le, MDCleveland, United StatesContact: Duc Le, MDTaking people
  • Optimal Medical GroupFresno, United StatesContact: Dr. Lucia Mireles-Chavez, MDTaking people
  • Scheer Medical WellnessNew York, United StatesContact: Dr. Alexandre Scheer, MDTaking people
  • R3 Anti Aging ScottsdaleScottsdale, United StatesContact: Dr. Sabrina Solt, NMDTaking people

About the trial

What the trial wants to find out

This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.

The 3 groups in the trial

  • 2cc WJ Allograft (Low Dose)Existing treatment, for comparison

    The 2cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Low Dose Group.

    Treatment: Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection

  • 3cc WJ Allograft (Medium Dose)Existing treatment, for comparison

    The 3cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Medium Dose Group.

    Treatment: Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection

  • 4cc WJ Allograft (High Dose)Existing treatment, for comparison

    The 4cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the High Dose Group.

    Treatment: Umbilical Cord Wharton's Jelly Allograft Intra-articular Knee Injection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for
Plain-language title
Umbilical cord tissue injections for knee osteoarthritis, tested for safetyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
23 September 2024